DiagnaMed Holdings Corp.: A Major Milestone in Hydrogen and Life Sciences Industries
Toronto, Ontario – April 14, 2025 – DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) (“DiagnaMed” or the “Company”), an innovative leader in technology solutions for the hydrogen and life sciences industries, has recently announced the successful completion of its private placement financing. The offering brought in gross proceeds of $397,510 by issuing 13,250,333 units at an issue price of $0.03 per unit.
Details of the Financing
Each unit consists of one common share in the capital of the company and one common share purchase warrant. The exercise price of the warrant is set at $0.05, allowing the warrant holder to acquire an additional common share for a period of 24 months from the closing of the offering.
Impact on DiagnaMed
This financing represents a significant step forward for DiagnaMed as it continues to develop and commercialize its advanced technologies in the hydrogen and life sciences industries. The proceeds from this financing will be used to further advance research and development, expand operations, and strengthen the Company’s balance sheet.
Impact on the World
DiagnaMed’s achievements in the hydrogen and life sciences industries are not only important for the Company but also have far-reaching implications for the world. The hydrogen industry is on the cusp of a major transformation, with increasing demand for clean, renewable energy sources. DiagnaMed’s technology solutions are at the forefront of this transition, offering more efficient and cost-effective methods for hydrogen production and storage.
In the life sciences sector, DiagnaMed’s innovations are contributing to advancements in diagnostics, therapeutics, and research. The Company’s technologies are helping to improve healthcare outcomes, reduce costs, and accelerate the pace of scientific discovery. As these technologies continue to evolve and be adopted on a larger scale, they will have a profound impact on the way we diagnose, treat, and prevent diseases.
Conclusion
DiagnaMed’s successful completion of its private placement financing marks an exciting milestone in the Company’s journey to revolutionize the hydrogen and life sciences industries. With a strong balance sheet and a commitment to innovation, DiagnaMed is poised to make a significant impact on the world through the development and commercialization of its advanced technology solutions.
- DiagnaMed Holdings Corp. completes private placement financing
- Gross proceeds of $397,510 from issuing 13,250,333 units
- Proceeds to be used for research and development, expansion, and balance sheet strengthening
- Significant impact on hydrogen and life sciences industries
- Contributing to clean, renewable energy and advancements in healthcare
